Jason Paul Steik, Chief Clinical Officer of Pennant Group, Inc. (NASDAQ: PNTG), filed a Form 4 on August 10, 2026, disclosing the sale of common stock on August 6, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Jason Paul Steik, Chief Clinical Officer of Pennant Group, Inc.
  • Transaction date: August 6, 2026
  • Shares disposed: 1,394 shares of common stock sold at $38.522 per share
  • Post-transaction ownership: 15,106 shares of common stock held directly
  • Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

Pennant Group Insider Share Sale Details and Ownership Following Transaction

According to the filing, Jason Paul Steik, serving as Chief Clinical Officer of Pennant Group, Inc., disposed of 1,394 shares of common stock on August 6, 2026, at a price of $38.522 per share. The transaction is coded "S," indicating a sale, and the shares were disposed of directly. The filing was signed by Kirk Cheney as attorney in fact on August 10, 2026.

Following the reported transaction, Steik directly holds 15,106 shares of Pennant Group common stock, according to the filing. No derivative securities transactions were reported in Table II of the form. The filing notes that the transaction was carried out under a written plan meeting the conditions of Rule 10b5-1(c), as indicated by the checked box on the form.

The filing was submitted as a Form 4 Statement of Changes in Beneficial Ownership, filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. Pennant Group, Inc. is listed on NASDAQ under the ticker PNTG, as stated in the issuer field of the filing.

What Was Disclosed

The filing discloses a single sale of 1,394 shares of Pennant Group common stock by Chief Clinical Officer Jason Paul Steik on August 6, 2026, at $38.522 per share, leaving him with direct ownership of 15,106 shares.